Hi LyneJ,
Hopefully you will never progress and need any therapy.
TerryH and Arizonian both gave you great answers. The problem we have as myeloma patients is that no "style" of therapy has shown a definitive overall survival advantage or quality of life advantage over another. This short 2 paragraphs including a quote from Dr. Rajkumar of Mayo sums it up perfectly IMO:
"Recent years have witnessed a flood of clinical trials incorporating the novel agents thalidomide, bortezomib, and lenalidomide into myeloma treatment. Yet despite the 20 new combination regimens that have been evaluated in the past 10 years, none has emerged as a clear frontrunner in terms of improving overall survival or quality of life, according to S. Vincent Rajkumar, MD, of Mayo Clinic.
As a result, “Clinicians are forced to make a choice not based on data, but based on opinion—and opinions vary,” said Dr. Rajkumar. The selection of initial therapy heretofore has been guided by whether a patient is eligible for autologous hematopoietic stem cell transplantation (ASCT) based on host factors such as age, organ function, and performance status. Thereafter, therapy selection was refi ned in accord with the aggressiveness of disease based on cytogenetic and gene-expression analysis."
http://chicago2012.asco.org/ASCODailyNews/myelomacontroversies.aspxWith respect to question #4, I would look at the Financial Disclosure Statement of the Doctor that is giving their opinion about the data they are presenting. Never forget that cancer therapy is big business. Many of the Doctors recieve money from "Big Pharma". That could influence their interpretation of data. It is also in an individual treatment centers financial interest to get as many patients to their facility as possible. Just another thing that makes it difficult to be a myeloma patient!
Mark